CAPLIPOINT

Caplin Point Laboratories Ltd.

NSE: CAPLIPOINT

BSE: 524742

Sector: Healthcare

Industry Group: Pharmaceuticals & Biotechnology

Industry: Pharmaceuticals

2,770.10-50.9 (-1.80%)

8 Sep, 12:00 AM

Overview

Analysis Statements Technicals Forecast Peers Resources News

Stock Scores

Quality Score

91.7 / 100

Value Score

32.3 / 100

Price Momentum Score

91.9 / 100

QVM Score

91.9 / 100

Key Metrics

Market Cap

21056.10

P/E (TTM)

31.54

P/B

5.87

P/S (TTM)

9.21

EV/EBITDA

25.08

CAPE (5Y)

45.76

ROE (TTM)

19.89

ROCE (TTM)

21.05

ROA (TTM)

17.68

Avg 3Y ROE

20.42

Earnings 3Y CAGR

6.19

Sales 3Y CAGR

14.70

Sales 5Y CAGR

15.32

Debt/Equity

0.00

Consensus TP

2505.00

Strong Buy %

Promoter Holding

70.57

Pledged %

0.00

Stock Analysis

Fundamental analysis overview of Caplin Point Laboratories Ltd. covering key investment insights, growth drivers, risk factors, and potential red flags.

Views

Red Flags

Positive

Strong price momentum

Price Momentum score of 91.9 indicates that the stock has strong price momentum. Research has shown that stocks with higher momentum continue to outperform in the near term

What is Price Momentum score?

91.9 / 100

Analysts have been raising forward EPS estimates

Analyst EPS estimate (consensus) for forward EPS has increased by 2.68% in the last 3 months, indicating earnings momentum

What is Earnings upgrade (3M)?

High and stable ROE

The company reported strong ROE of 19.89% for 12-month ended 30 Jun 2026 and ROE declined marginally by -80 bps from 1 year ago

What is ROE (FY)?

High and stable operating margin

The company reported strong operating margin of 31.41% for 12-month ended 30 Jun 2026 and operating margin improved marginally by 91 bps from 1 year ago

What is Operating profit margin?

Moderate revenue growth and above median growth of industry

The company delivered moderate revenue growth of 15.01% for 12-month ended 30 Jun 2026 and the growth was 4.42 percentage points higher than median growth of industry

What is Sales growth (1Y)?

Median: 10.59

Value 15.01

-99.6111701.8

Moderate EPS growth and above median growth of industry

The company delivered moderate EPS growth of 19.73% for 12-month ended 30 Jun 2026 and the growth was 12.53 percentage points higher than median growth of industry

What is EPS growth (1Y)?

Low Debt to Equity, not much change from last year

The company has low Debt to Equity of 0.0 as on 30 Jun 2026 and Debt to Equity remained same in the last 1 year

What is Debt to Equity?

Consistently pays dividend

The company has not missed dividend payments once in the last 10 financial years

What is Dividend streak?

Company is net cash

The company is net cash i.e., cash and cash equivalents exceed total debt indicating a healthy balance sheet

What is Net Debt ?

Negative

Expensive and at same valuation levels as industry median P/E

PE TTM of 31.54 indicates that the stock is expensive on a standalone basis. Discount to industry median P/E is modest at -0.76%

What is P/E Ratio?

Median: 31.78

Value 31.54

-0.96721.13

Low dividend yield

The company has a low dividend yield of 0.25%

What is Dividend yield?

Neutral

Company's earnings are of moderate quality

Earnings quality score of 52.1 indicates that the company's earnings are of moderate quality. Earnings quality is measured using combination of earnings persistence, probability of manipulation and earnings to cash conversion

What is Earnings quality score?

52.1 / 100

Financial Snapshot

See detailed analysis

Multi-year trends for Caplin Point Laboratories Ltd. covering revenue, net profit, ROE, and EBITDA for a quick view of financial health over time.

Net Revenue FY

Profit After Tax FY

ROE FY

EBITDA FY

Caplin Point Laboratories Ltd. Shareholding Pattern

Quarterly breakdown of Caplin Point Laboratories Ltd. ownership including promoter, FII, DII, mutual fund, and public holdings as disclosed to NSE/BSE.

	Mar 2020	Jun 2020	Sep 2020	Dec 2020	Mar 2021	Jun 2021	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Total Promoter	69.03	69.03	69.03	69.03	69.03	69.03	69.03	68.91	68.89	68.88	68.88	68.80	70.66	70.63	70.63	70.62	70.62	70.56	70.56	70.56	70.56	70.56	70.57	70.57	70.57	70.57
Indian Promoter	69.03	69.03	69.03	69.03	69.03	69.03	69.03	68.91	68.89	68.88	68.88	68.80	70.66	70.63	70.63	70.62	70.62	70.56	70.56	70.56	70.56	70.56	70.57	70.57	70.57	70.57
Foreign Promoter	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Institutions	4.47	3.14	2.80	2.74	1.96	2.63	2.95	3.33	3.32	3.15	3.27	3.36	3.01	2.95	3.29	3.26	4.43	4.86	5.53	6.97	7.74	8.39	8.61	8.64	8.29	8.24
Mutual Funds / UTI	0.00	0.00	0.31	0.38	0.45	0.99	1.14	1.16	1.19	1.06	1.05	1.04	0.57	0.05	0.05	0.41	1.06	1.32	1.62	1.86	1.74	1.93	1.79	1.97	2.02	2.03
FI/Bank/Insurance	0.04	0.06	0.24	0.72	0.83	0.45	0.00	0.00	0.00	0.00	0.00	0.08	0.00	0.01	0.14	0.00	0.00	0.08	0.15	0.14	0.20	0.22	0.23	0.01	0.01	0.03
Govt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
FII	4.43	3.08	2.25	1.64	0.68	1.15	1.76	2.11	2.07	2.03	2.15	2.24	2.36	2.68	3.08	2.83	3.33	3.37	3.71	4.86	5.73	6.17	6.48	6.55	6.15	5.75
Other Institutions	0.00	0.00	0.00	0.00	0.00	0.05	0.05	0.05	0.05	0.05	0.07	0.00	0.07	0.21	0.03	0.02	0.02	0.09	0.06	0.11	0.06	0.07	0.11	0.10	0.11	0.43
Non-Institution	26.50	27.83	28.17	28.23	29.01	28.34	28.02	27.76	27.78	27.97	27.85	27.84	26.34	26.42	26.08	26.10	24.95	24.57	23.91	22.47	21.70	21.05	20.82	20.79	21.14	21.18
Bodies Corporate	1.42	1.52	1.31	1.20	1.34	1.62	1.99	1.84	1.85	1.99	2.68	2.70	1.83	1.81	1.77	1.63	1.41	1.16	0.99	0.91	0.85	0.95	0.98	0.96	1.53	1.56
Others (incl. Retail) No. of shareholders	25.08 29,773	26.31 37,816	26.86 62,217	27.03 66,195	27.67 67,787	26.72 69,204	26.03 83,125	25.92 85,239	25.93 83,486	25.98 84,526	25.17 84,183	25.14 82,322	24.51 81,793	24.61 78,581	24.31 77,661	24.47 79,032	23.54 80,970	23.41 79,941	22.92 95,652	21.56 92,178	20.85 95,862	20.10 93,597	19.84 93,174	19.83 93,131	19.61 93,187	19.62 93,581

Holdings and Presence

Indices and prominent investors with a stake in this stock.

Index Presence

#	Index	Weight	Rank
1	Nifty 500 Momentum Quality 50	0.38%	48 / 50
2	Nifty Smallcap 250	0.23%	178 / 249
3	Nifty 500	0.03%	368 / 499
4	Nifty Total Market	0.02%	470 / 749

Prominent Investor Holdings

Bulk, Block and Insider Trades

Recent bulk deals, block deals, and insider trading activity in Caplin Point Laboratories Ltd. shares as reported to NSE and BSE.

Name	Month	Transaction	Holding % pre transaction	Average price	Qty.	Transaction value
Arulsudar Natrajan Employee	November-2021	Market Sale (Disposal) 24th Nov 2021	0.00 %	₹ 831.00	1.50 k	₹ 12.46 lac
Arulsudar Natrajan Employee	November-2021	Market Sale (Disposal) 24th Nov 2021	0.00 %	₹ 832.00	2.00 k	₹ 16.64 lac
Sathish Krishnan Employee	November-2021	Market Sale (Disposal) 24th Nov 2021	0.01 %	₹ 811.51	5.00 k	₹ 40.58 lac
Arulsudar Natrajan Employee	November-2021	Market Sale (Disposal) 19th Nov 2021	0.01 %	₹ 866.05	1.50 k	₹ 12.99 lac
Subramanian Narayanaswamy Employee	November-2021	Market Sale (Disposal) 19th Nov 2021	0.01 %	₹ 870.00	100.00	₹ 87.00 k
Subramanian Narayanswamy Employee	November-2021	Market Sale (Disposal) 19th Nov 2021	0.01 %	₹ 867.75	4.90 k	₹ 42.52 lac

Corporate Actions

History of Caplin Point Laboratories Ltd. dividends, bonus issues, stock splits, rights issues, and other corporate events.

Dividend₹ 4/share
Record date: 18th Sep 2026Ex-date: 18th Sep 2026
Announced on: 12th Aug 2026
Dividend₹ 4/share
Record date: 30th May 2026Ex-date: 29th May 2026
Announced on: 14th May 2026
Dividend₹ 3/share
Record date: 12th Sep 2025Ex-date: 12th Sep 2025
Announced on: 7th Aug 2025
Dividend₹ 3/share
Record date: 30th May 2025Ex-date: 30th May 2025
Announced on: 15th May 2025
Dividend₹ 2.50/share
Record date: 23rd Sep 2024Ex-date: 23rd Sep 2024
Announced on: 7th Aug 2024

Company Profile

Overview of Caplin Point Laboratories Ltd. covering business description, industry classification, key management, financial ratios, and listed exchange details.

Caplin Point Laboratories Limited is an India-based pharmaceutical company with a business model catering predominantly to emerging markets of Latin America and Africa. The Company has also entered regulated markets such as the United States through its Subsidiary, Caplin Steriles Limited. The Compa...

Key personnel

Mr. G. Venkatram

Compliance Officer, General Counsel, Company Secretary

Mr. Chingelput Chellappan PaarthipanD

Non-Executive Chairman of the Board

Mr. Ashok Gorkey PartheebanD

Non-Executive Vice Chairman of the Board

Mr. Vivek Siddharth PartheebanD

Non-Executive Vice Chairman of the Board

Mr. D. MuralidharanD

Chief Financial Officer, Whole-Time Director

Dr. Sridhar GanesanD

Managing Director, Executive Director

Mr. S. DeenadhayalanD

Non-Executive Independent Director

Mr. Komattu Chacko JohnD

Non-Executive Independent Director

View all

Incorporated on

16 Apr 1990

Last Annual

31 Mar 2026

Last Interim

30 Jun 2026

No. of Employees

1,024

IPO date

16 Nov 1994

Free Float

2,01,90,858

Website

https://www.caplinpoint.net/

Phone no.

+914428156653

Address

3rd Floor, Ashvich Towers, No 3,, Developed Plots Industrial Estate, Perungudi, CHENNAI, 600096, India

Frequently Asked Questions

What is the current share price of Caplin Point Laboratories Ltd.?

The current share price of Caplin Point Laboratories Ltd. is ₹ 2,770.10 as of 8 Sep 2026.

What is the market capitalisation of Caplin Point Laboratories Ltd.?

The market capitalisation of Caplin Point Laboratories Ltd. stands at ₹ 21,056.10 Cr.

What is the PE ratio of Caplin Point Laboratories Ltd.?

The Price-to-Earnings (PE) ratio of Caplin Point Laboratories Ltd. is 31.54 as of the latest trailing twelve months data.

What is the ROE and ROCE of Caplin Point Laboratories Ltd.?

Caplin Point Laboratories Ltd. has a Return on Equity (ROE) of 19.89% and a Return on Capital Employed (ROCE) of 21.05% as per the latest financial reports.

What is the 52-week high and low of Caplin Point Laboratories Ltd.?

The 52-week high of Caplin Point Laboratories Ltd. is - and the 52-week low is -.

What is the dividend yield of Caplin Point Laboratories Ltd.?

The dividend yield of Caplin Point Laboratories Ltd. is 0.25% based on the current market price.

What is the FII and DII holding in Caplin Point Laboratories Ltd.?

Foreign Institutional Investors (FII) hold 5.75%, Domestic Institutional Investors (DII) hold 2.06% and retail/public investors hold 19.62% of Caplin Point Laboratories Ltd. shares.

What sector does Caplin Point Laboratories Ltd. belong to?

Caplin Point Laboratories Ltd. operates in the Healthcare sector.

What is the beta of Caplin Point Laboratories Ltd.?

The beta of Caplin Point Laboratories Ltd. is 0.92, indicating its price volatility relative to the broader market. Over the past 1 year, Caplin Point Laboratories Ltd. has delivered an absolute return of 30.15%.

What is the RSI of Caplin Point Laboratories Ltd.?

The 14-day Relative Strength Index (RSI) of Caplin Point Laboratories Ltd. is 62.12, placing it approaching overbought territory. An RSI above 70 is considered overbought and below 30 is considered oversold.

Caplin Point Laboratories Ltd.

Stock Scores

Key Metrics

Share Price

Stock Analysis

Financial Snapshot

Caplin Point Laboratories Ltd. Shareholding Pattern

Holdings and Presence

Bulk, Block and Insider Trades

Corporate Actions

Company Profile

Frequently Asked Questions

Stock Analysis

Company Profile

Corporate Actions

Holdings and Presence